← FDA DRUG APPROVALS

FDA NDA · NDA022532

DROSPIRENONE/ETHINYL ESTRADIOL/LEVOMEFOLATE CALCIUM AND LEVOMEFOLATE CALCIUM

Sponsor: BAYER HLTHCARE

APPLICATION
NDA022532
TYPE
NDA
ORIGINAL APPROVAL
2010-09-24
LATEST ACTION
2023-05-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

BEYAZ · ReferencePrescription
DROSPIRENONE 3MG,N/A, ETHINYL ESTRADIOL 0.02MG,N/A, LEVOMEFOLATE CALCIUM 0.451MG,0.451MG · TABLET · ORAL

Approval history

2023-05-19Labeling · Supplement 10 · standard — Letter ↗AP
2022-04-29Labeling · Supplement 11 · standard — Letter ↗AP
2017-08-09Labeling · Supplement 9 · standard — Label ↗AP
2016-05-11Manufacturing (CMC) · Supplement 7 · standardAP
2015-06-01Labeling · Supplement 6 · standard — Label ↗AP
2012-04-10Labeling · Supplement 4 · standard — Label ↗AP
2012-02-13Efficacy · Supplement 1 · standard — Review ↗AP
2010-09-24Type 4 - New Combination · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →